Personalized Therapy and Clinical Outcomes for Congenital Heart Disease

Dear Colleagues,

Congenital heart disease (CHD) remains one of the most prevalent and challenging health conditions. Despite significant advances made in the diagnosis and treatment of CHD, there is still considerable variability in clinical outcomes among affected individuals. This diversity underscores the complex interplay of genetic, environmental, and developmental factors that contribute to the heterogeneous nature of CHD. Tailoring treatment strategies to the unique physiological characteristics of each patient holds the promise of optimizing clinical outcomes and improving long-term prognoses. From genomic profiling to advanced imaging techniques, the tools available for personalized medicine in CHD continue to evolve rapidly, offering unprecedented opportunities for precision diagnosis and targeted interventions. This Special Issue of the Journal of Clinical Medicine is dedicated to exploring the latest developments and breakthroughs in personalized therapy for CHD and their impacts on clinical outcomes. By bringing together cutting-edge research and clinical insights from experts in this field, we aim to shed light on the current state-of-the-art approaches, as well as the challenges and opportunities that lie ahead in the pursuit of personalized care for individuals with CHD. We invite original research articles and reviews that contribute to our understanding of personalized therapy for ACHD and its implications for clinical practice.

This Special Issue aims to:

• Provide an overview of the unmet needs of the contemporary cohort of the aging CHD population, aiming to improve the outcomes and reduce the cardiac and extracardiac long-term complications.
• Propose new strategies for the CHD cardiologists to care for the special needs of this extremely heterogenous population.
• Promote a patient-centered care process, with the main aim of improving the perceived quality of life.
• Describe the new knowledge gathered on the genetic and genomic profiling of CHD patients—from risk prediction to targeted therapies.
• Illustrate the advances in imaging modalities for personalized diagnoses and treatment planning.
• Propose a more extensive use of biomarkers in CHD for risk stratification and prognostication in the everyday clinical practice.
• Provide insights into the novel, therapeutic, and preventive approches in CHD, with a special focus on pharmacogenomics and personalized drug therapies.
• Propose new potential pathways for the management of specific lesions using a patient-tailored approach.
• Describe the potential impact on the long-term outcomes of patient-tailored therapies applied to the special CHD population.

Dr. Giancarlo Scognamiglio
Dr. Flavia Fusco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• personalized therapy
• clinical outcome
• heart failure therapy
• anti-arrhythmic therapy
• sudden death prevention
• adult congenital heart failure
• prognosis